Epstein-Barr virus antibody responses and clinical illness in renal transplant recipients

Stephen C. Marker; Nancy L. Ascher; Janal M. Kalis; Richard L. Simmons; John S. Najarian; Henry H. Balfour

Epstein-Barr virus antibody responses and clinical illness in renal transplant recipients

Stephen C. Marker, Nancy L. Ascher, Janal M. Kalis, Richard L. Simmons, John S. Najarian, Henry H. Balfour

Research output: Contribution to journal › Article › peer-review

Abstract

Among 88 renal transplant recipients evaluated for a change in Epstein-Barr virus (EBV) antibody status in the period after transplant, 22 showed a 4-fold rise and eight showed an 8-fold or greater rise in EBV antibody. Among the patients with an 8-fold or greater EBV antibody rise, the occurrence of fever was frequent, one patient developed a lymphoproliferative reaction, and one died with a malignant EBV infection. Patients without pretransplant antibody showed a longer mean time to antibody rise (104 ± 23 days) than did those patients with pretransplant antibody (19 ± 7 days). The longer incubation period in patients without pretransplant antibody was in the expected range for primary EBV infections. Both primary and secondary (reactivation) EBV infections occur in renal transplant patients. These infections may be associated with prolonged fever and, in unusual circumstances, may cause dramatic lymphoproliferative disease.

Original language	English (US)
Pages (from-to)	433-440
Number of pages	8
Journal	Surgery
Volume	85
Issue number	4
State	Published - Apr 1979

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Find It

Find It at U of M Libraries

Cite this

@article{283443b4b91d46f781f7350adcc6603f,

title = "Epstein-Barr virus antibody responses and clinical illness in renal transplant recipients",

abstract = "Among 88 renal transplant recipients evaluated for a change in Epstein-Barr virus (EBV) antibody status in the period after transplant, 22 showed a 4-fold rise and eight showed an 8-fold or greater rise in EBV antibody. Among the patients with an 8-fold or greater EBV antibody rise, the occurrence of fever was frequent, one patient developed a lymphoproliferative reaction, and one died with a malignant EBV infection. Patients without pretransplant antibody showed a longer mean time to antibody rise (104 ± 23 days) than did those patients with pretransplant antibody (19 ± 7 days). The longer incubation period in patients without pretransplant antibody was in the expected range for primary EBV infections. Both primary and secondary (reactivation) EBV infections occur in renal transplant patients. These infections may be associated with prolonged fever and, in unusual circumstances, may cause dramatic lymphoproliferative disease.",

author = "Marker, {Stephen C.} and Ascher, {Nancy L.} and Kalis, {Janal M.} and Simmons, {Richard L.} and Najarian, {John S.} and Balfour, {Henry H.}",

year = "1979",

month = apr,

language = "English (US)",

volume = "85",

pages = "433--440",

journal = "Surgery",

issn = "0039-6060",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Epstein-Barr virus antibody responses and clinical illness in renal transplant recipients

AU - Marker, Stephen C.

AU - Ascher, Nancy L.

AU - Kalis, Janal M.

AU - Simmons, Richard L.

AU - Najarian, John S.

AU - Balfour, Henry H.

PY - 1979/4

Y1 - 1979/4

N2 - Among 88 renal transplant recipients evaluated for a change in Epstein-Barr virus (EBV) antibody status in the period after transplant, 22 showed a 4-fold rise and eight showed an 8-fold or greater rise in EBV antibody. Among the patients with an 8-fold or greater EBV antibody rise, the occurrence of fever was frequent, one patient developed a lymphoproliferative reaction, and one died with a malignant EBV infection. Patients without pretransplant antibody showed a longer mean time to antibody rise (104 ± 23 days) than did those patients with pretransplant antibody (19 ± 7 days). The longer incubation period in patients without pretransplant antibody was in the expected range for primary EBV infections. Both primary and secondary (reactivation) EBV infections occur in renal transplant patients. These infections may be associated with prolonged fever and, in unusual circumstances, may cause dramatic lymphoproliferative disease.

AB - Among 88 renal transplant recipients evaluated for a change in Epstein-Barr virus (EBV) antibody status in the period after transplant, 22 showed a 4-fold rise and eight showed an 8-fold or greater rise in EBV antibody. Among the patients with an 8-fold or greater EBV antibody rise, the occurrence of fever was frequent, one patient developed a lymphoproliferative reaction, and one died with a malignant EBV infection. Patients without pretransplant antibody showed a longer mean time to antibody rise (104 ± 23 days) than did those patients with pretransplant antibody (19 ± 7 days). The longer incubation period in patients without pretransplant antibody was in the expected range for primary EBV infections. Both primary and secondary (reactivation) EBV infections occur in renal transplant patients. These infections may be associated with prolonged fever and, in unusual circumstances, may cause dramatic lymphoproliferative disease.

UR - http://www.scopus.com/inward/record.url?scp=0018616359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018616359&partnerID=8YFLogxK

M3 - Article

C2 - 219556

AN - SCOPUS:0018616359

SN - 0039-6060

VL - 85

SP - 433

EP - 440

JO - Surgery

JF - Surgery

IS - 4

ER -

Epstein-Barr virus antibody responses and clinical illness in renal transplant recipients

Abstract

UN SDGs

Find It

Other files and links

Fingerprint

Cite this